{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:51:20Z","timestamp":1760266280789,"version":"3.40.4"},"reference-count":4,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2000]]},"abstract":"<jats:p>&lt;i&gt;Purpose:&lt;\/i&gt; This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer. &lt;i&gt;Patients and Methods:&lt;\/i&gt; Chemonaive patients with locally advanced inoperable, recurrent or metastatic gastric cancer were treated with 15 mg\/m&lt;sup&gt;2&lt;\/sup&gt; i.v. mitomycin C as bolus on day 1 of a 7-week cycle followed by a 2-hour infusion of folinic acid (500 mg\/m&lt;sup&gt;2&lt;\/sup&gt;) and a 24-hour infusion of 5-FU (2,600 mg\/m&lt;sup&gt;2&lt;\/sup&gt;) given on days 1, 8, 15, 22, 29, and 36 as outpatient treatment. &lt;i&gt;Results:&lt;\/i&gt; Thirty evaluable patients (median age 58 years and median ECOG performance status 1) received 1\u20134 cycles (median 3). 53% of the patients had liver metastases. Treatment-related toxicity was low with 10% of patients experiencing diarrhea \u2265grade 3, 3% mucositis grade 3 and 3% nausea grade 3 (CTC). Hematological toxicity was mild with 13% thrombopenia grade 3 and no leukopenia grade 4. Eleven patients achieved a partial remission (major response rate 37%; 95% confidence interval 22\u201353%). Median time to progression was 5 months and median overall survival time was 7 months. &lt;i&gt;Conclusion:&lt;\/i&gt; This regimen is a well-tolerated outpatient treatment for patients with advanced gastric cancer with efficacy being comparable to other chemotherapy protocols.<\/jats:p>","DOI":"10.1159\/000012130","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T15:43:24Z","timestamp":1050421404000},"page":"14-17","source":"Crossref","is-referenced-by-count":12,"title":["Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil plus Folinic Acid in Combination with Mitomycin C for the Treatment of Advanced Gastric Cancer"],"prefix":"10.1159","volume":"59","author":[{"given":"Albrecht","family":"Kretzschmar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Thuss-Patience","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Benter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"D\u00f6rken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus-Henning","family":"K\u00f6hne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2000,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008243606668"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690350"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008263516099"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050074"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/12130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/12130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:56:41Z","timestamp":1745470601000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000012130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":4,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2000,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000012130","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2000]]}}}